The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Open accessAbstract
Objective: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods: Amyloid‐β 1 to 42 peptide (Aβ 1–42), total tau (t‐tau), and tau phosphorylated at the threonine 181 were measured in (1) cerebrospinal fluid (CSF) samples obtained during baseline evaluation of 100 mild AD, 196 mild cognitive impairment, and 114 elderly cognitively normal (NC) subjects in ADNI; and (2) independent 56 autopsy‐confirmed AD cases and 52 age‐matched elderly NCs using a multiplex immunoassay. Detection of an AD CSF profile for t‐tau and Aβ 1–42 in ADNI subjects was achieved using receiver operating characteristic cut points and logistic regression models derived from the autopsy‐confirmed CSF data. Results: CSF Aβ 1–42 was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%. In the ADNI cohort, a logistic regression model for Aβ 1–42, t‐tau, and APO ε 4 allele count provided the best assessment delineation of mild AD. An AD‐like baseline CSF profile for t‐tau/Aβ 1–42 was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study. Interpretation: The CSF biomarker signature of AD defined by Aβ 1–42 and t‐tau in the autopsy‐confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD. Ann Neurol 2009
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A preponderance of evidence supports the interpretation that PIB uptake and CSF Aβ42 are reliable surrogate markers of amyloid plaque pathology in living subjects (15-19).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased concentrations of extracellular soluble phosphorylated tau (p-tau) and total tau (t-tau) constitute a reliable index of this intracellular process in mild cognitive impairment due to AD2,3 and AD dementia.2,4”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Abnormal CSF Aβ42 values were defined using the previously established cut-off of <192 ng/L57–59.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationMueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Self-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Self-citationConsensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 711
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1016/S1474-4422(03)00530-1 · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 1,012
Dammer, E. B., Ping, L., Duong, D. M., Modeste, E. S., Seyfried, N. T., Lah, J. J., Levey, A. I., & Johnson, E. C. B. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01113-5 · Cited by 188
Hamilton, R. H., Patel, S. V., Lee, E. B., Jackson, E. M., Lopinto, J., Arnold, S. E., Clark, C. M., Basil, A. K., Shaw, L. M. J., Xie, S. X., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22015 · Cited by 185
Self-citationDeregulated Cdk5 activity is involved in inducing Alzheimer's disease
Shukla, V., Skuntz, S., & Pant, H. C. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.015 · Cited by 185
APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern
Risacher, S. L., Kim, S., Nho, K. T., Foroud, T., Shen, L., Petersen, R. C., Jack, C. R., Beckett, L. A., Aisen, P. S. S., Koeppe, R. A., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.03.003 · Cited by 191
Self-citationGold, B. T., Johnson, N. F., & Powell, D. (2013) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2013.09.037 · Cited by 185
Single molecule enzyme-linked immunosorbent assays: Theoretical considerations
Chang, L., Rissin, D. M., Fournier, D. R., Piech, T., Patel, P. P., Wilson, D. H., & Duffy, D. C. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.02.011 · Cited by 185
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
Ashton, N. J., Benedet, A. L., Pascoal, T. A., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Mathotaarachchi, S., Therriault, J., Savard, M., Chamoun, M., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103836 · Cited by 184
Self-citationGordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D. M., Cairns, N. J., et al. (2016) · Brain · doi:10.1093/brain/aww139 · Cited by 184
A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid
Savage, M. J., Kalinina, J., Wolfe, A. L., Tugusheva, K., Korn, R., Cash-Mason, T., Maxwell, J. W., Hatcher, N. G., Haugabook, S. J., Wu, G., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1675-13.2014 · Cited by 187
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12422 · Cited by 184
Self-citationCSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182
Self-citationCSF Aβ42 and tau in Parkinson's disease with cognitive impairment
Montine, T. J., Shi, M. Y., Quinn, J. F., Peskind, E. R., Craft, S., Ginghină, C., Chung, K. A., Kim, H., Galasko, D. R., Jankovic, J. J., et al. (2010) · Movement Disorders · doi:10.1002/mds.23287 · Cited by 185
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
Blennow, K., & Zetterberg, H. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1177 · Cited by 180
Self-citationZhang, X., Mormino, E. C., Sun, N., Sperling, R. A., Sabuncu, M. R., Yeo, B. T. T., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611073113 · Cited by 174
Self-citationDong, A., Toledo, J. B., Honnorat, N., Doshi, J. J., Varol, E., Sotiras, A., Wolk, D. A., Trojanowski, J. Q., Davatzikos, C. A., & Initiative, A. D. N. (2016) · Brain · doi:10.1093/brain/aww319 · Cited by 183
Self-citationFactors affecting Aβ plasma levels and their utility as biomarkers in ADNI
Toledo, J. B., Vanderstichele, H., Figurski, M., Aisen, P. S. S., Petersen, R. C., Weiner, M. W., Jack, C. R., Jagust, W., DeCarli, C. S., Toga, A. W., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0861-8 · Cited by 182
Self-citationIturria‐Medina, Y., Sotero, R. C., Toussaint, P. J., Evans, A. C., & Initiative, A. T. A. D. N. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003956 · Cited by 185
Self-citationPolygenic risk of Alzheimer disease is associated with early- and late-life processes
Mormino, E. C., Sperling, R. A., Holmes, A. J., Buckner, R. L., Jager, P. L. D., Smoller, J. W., Sabuncu, M. R., Initiative, A. D. N., Initiative, A. D. N., Weiner, M. W., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002922 · Cited by 174
Self-citationPrediction and classification of Alzheimer disease based on quantification of MRI deformation
Long, X., Chen, L., Jiang, C., Zhang, L., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173372 · Cited by 180
Self-citationEcology of the Aging Human Brain
Sonnen, J. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.157 · Cited by 174
PET amyloid-beta imaging in preclinical Alzheimer's disease
Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 188
Lee, G. J., Lu, P. H., Hua, X., Lee, S., Wu, S., Nguyen, K., Teng, E., Leow, A., Jack, C. R., Toga, A. W., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.024 · Cited by 182
Report of the task force on designing clinical trials in early (predementia) AD
Aisen, P. S. S., Andrieu, S., Sampaio, C., Carrillo, M. C., Khachaturian, Z. S., Dubois, B., Feldman, H., Petersen, R. C., Siemers, E., Doody, R. S., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e318207b1b9 · Cited by 173
Self-citationAge and diagnostic performance of Alzheimer disease CSF biomarkers
Mattsson, N., Rosén, E., Hansson, O., Andreasen, N. C., Parnetti, L., Jonsson, M. A. G., Herukka, S., van der Flier, W. M., Blankenstein, M. A., Ewers, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182477eed · Cited by 172
Self-citationPortelius, E., Olsson, B., Höglund, K., Cullen, N. C., Kvartsberg, H., Andréasson, U., Zetterberg, H., Sandelius, Å., Shaw, L. M. J., Lee, V. M. ‐., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1851-x · Cited by 171
Self-citationHeterogeneous patterns of brain atrophy in Alzheimer's disease
Poulakis, K., Pereira, J. B., Mecocci, P., Vellas, B. J., Tsolaki, M., Kłoszewska, I., Soininen, H. S., Lovestone, S., Simmons, A., Wahlund, L., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.01.009 · Cited by 160
Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease
Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., Olazarán, J., Antúnez, C., Izagirre, A., Ecay-Torres, M., Estanga, A., Clerigué, M., Guisasola, M. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001859 · Cited by 163
Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
McGrowder, D. A., Miller, F. G., Vaz, K., Nwokocha, C. R., Wilson-Clarke, C. F., Anderson, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 169
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180
Self-citationThe Apolipoprotein E Antagonistic Pleiotropy Hypothesis: Review and Recommendations
Tuminello, E. R., & Han, S. D. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/726197 · Cited by 175
Obstructive Sleep Apnea and Longitudinal Alzheimer's Disease Biomarker Changes
Bubu, O. M., Pirraglia, E., Andrade, A. G., Sharma, R. A., Giménez, S., Umasabor‐Bubu, O. Q., Hogan, M. M., Shim, A., Mukhtar, F., Sharma, N. K., et al. (2018) · SLEEP · doi:10.1093/sleep/zsz048 · Cited by 176
Self-citationClinical and multimodal biomarker correlates of ADNI neuropathological findings
Toledo, J. B., Cairns, N. J., Da, X., Chen, K., Carter, D. R., Fleisher, A., Householder, E., Ayutyanont, N., Roontiva, A., Bauer, R. J., III, et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-65 · Cited by 171
Self-citationNano-biosensors to detect beta-amyloid for Alzheimer's disease management
Kaushik, A. K., Jayant, R. D., Tiwari, S., Vashist, A., & Nair, M. G. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.01.065 · Cited by 167
18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
Tsai, R. M., Bejanin, A., Lesman-Segev, O., LaJoie, R., Visani, A., Bourakova, V., O’Neil, J. P., Janabi, M., Baker, S., Lee, S. E., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0470-7 · Cited by 164
Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline
Risacher, S. L., Anderson, W. H., Charil, A., Castelluccio, P. F., Shcherbinin, S., Saykin, A. J., Schwarz, A. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M. W., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004670 · Cited by 163
Self-citationIrwin, D. J., & Hurtig, H. I. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000444 · Cited by 177
Sutphen, C. L., McCue, L., Herries, E. M., Xiong, C., Ladenson, J. H., Holtzman, D. M., Fagan, A. M., & On behalf of, A. D. N. I. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.012 · Cited by 162
Characterizing Alzheimer's disease using a hypometabolic convergence index
Chen, K., Ayutyanont, N., Langbaum, J. B. S., Fleisher, A., Reschke, C., Lee, W., Liu, X., Bandy, D., Alexander, G. E., Thompson, P. M., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.049 · Cited by 165
Self-citationSohn, D., Shpanskaya, K., Lucas, J. E., Petrella, J. R., Saykin, A. J., Tanzi, R. E., Samatova, N. F., & Doraiswamy, P. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-25377-w · Cited by 161
Ritchie, C. W., Smailagic, N., Noel-Storr, A. H., Takwoingi, Y., Flicker, L. A., Mason, S., & McShane, R. H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008782.pub4 · Cited by 167
Biological markers of amyloid β-related mechanisms in Alzheimer's disease
Hampel, H. J., Shen, Y., Walsh, D. M., Aisen, P. S. S., Shaw, L. M., Zetterberg, H., Trojanowski, J. Q., & Blennow, K. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.024 · Cited by 162
Self-citationBasal forebrain volume reliably predicts the cortical spread of Alzheimer’s degeneration
Fernández‐Cabello, S., Kronbichler, M., Dijk, K. R. A. V., Goodman, J. A., Spreng, R. N., Schmitz, T. W., & Initiative, O. B. O. T. A. D. N. (2020) · Brain · doi:10.1093/brain/awaa012 · Cited by 159
Impaired glycemia increases disease progression in mild cognitive impairment
Morris, J. K., Vidoni, E. D., Honea, R. A., & Burns, J. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.033 · Cited by 163
Gupta, Y., Lama, R. K., Kwon, G., & Initiative, A. D. N. (2019) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2019.00072 · Cited by 161
Self-citationNanoparticle formulations in the diagnosis and therapy of Alzheimer's disease
Gupta, J., Fatima, M. T., Islam, Z., Khan, R. H., Uversky, V. N., & Salahuddin, P. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.02.156 · Cited by 163
Initiative, F. T. A. D. N., Skinner, J., Carvalho, J. O., Potter, G. G., Thames, A., Zelinski, E., Crane, P. K., & Gibbons, L. E. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9166-3 · Cited by 151
Self-citationNeuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection
Risacher, S. L., & Saykin, A. J. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185535 · Cited by 163
Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction
Evered, L. A., SILBERT, B. S., Scott, D. A., Ames, D. J., Maruff, P. T., & Blennow, K. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000953 · Cited by 153
Self-citationCognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition
Vemuri, P., Weigand, S. D., Przybelski, S. A., Knopman, D. S., Smith, G. E., Trojanowski, J. Q., Shaw, L. M. J., DeCarli, C. S., Carmichael, O. T., Bernstein, M. A., et al. (2011) · Brain · doi:10.1093/brain/awr049 · Cited by 164
Self-citationBiomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Dickerson, B. C. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00055 · Cited by 160
Wang, M. J., Yi, S., Han, J.-Y., Park, Y. H., Jang, J., Chun, I. K., Kim, S. E., Lee, B. S., Kim, G. J., Yu, J. S., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0324-0 · Cited by 152
CBIR system using Capsule Networks and 3D CNN for Alzheimer's disease diagnosis
Kruthika, K. R., Rajeswari, P., Maheshappa, H., & Initiative, A. D. N. (2019) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2018.12.001 · Cited by 145
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42
Schott, J. M., Bartlett, J. W., Fox, N. C., Barnes, J., & Initiative, A. D. N. (2010) · Annals of Neurology · doi:10.1002/ana.22315 · Cited by 146
Self-citationMetabolomic changes in autopsy‐confirmed Alzheimer's disease
Kaddurah-Daouk, R. F., Rozen, S., Matson, W. R., Han, X., Hulette, C. M., Burke, J. R., Doraiswamy, P. M., & Welsh-Bohmer, K. A. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.001 · Cited by 145
Cognitive reserve and clinical progression in Alzheimer disease
van Loenhoud, A. C., van der Flier, W. M., Wink, A. M., Dicks, E., Groot, C., Twisk, J. W. R., Barkhof, F., Scheltens, P., Ossenkoppele, R., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000007821 · Cited by 159
Self-citationCaroli, A., & Frisoni, G. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.024 · Cited by 150
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
Gisslén, M., Krut, J. J., Andréasson, U., Blennow, K., Cinque, P. M., Brew, B. J., Spudich, S., Hagberg, L., Rosengren, L., Price, R. W., et al. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-63 · Cited by 147
Self-citationThe Past and the Future of Alzheimer’s Disease Fluid Biomarkers
Blennow, K., & Zetterberg, H. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170773 · Cited by 154
Self-citationFinding useful biomarkers for Parkinson’s disease
Chen‐Plotkin, A. S., Albin, R. L., Alcalay, R. N., Babcock, D., Bajaj, V. S., Bowman, D., BUKO, A. M., Cedarbaum, J. M., Chelsky, D., Cookson, M. R., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6003 · Cited by 145
Hyperphosphorylation and Cleavage at D421 Enhance Tau Secretion
Plouffe, V., Mohamed, N., Rivest‐McGraw, J., Bertrand, J., Lauzon, M., & Leclerc, N. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036873 · Cited by 159
The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI)
Risacher, S. L. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00011 · Cited by 151
Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 147
Self-citationBiomarkers in Alzheimer's disease drug development
Blennow, K. (2010) · Nature Medicine · doi:10.1038/nm.2221 · Cited by 145
Self-citationShapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3405 · Cited by 145
Self-citationHerukka, S.-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.009 · Cited by 141
Self-citationDiagnosis and biomarkers of predementia in Alzheimer's disease
Forlenza, O. V., Diniz, B. S., & Gattaz, W. F. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-89 · Cited by 160
Ferreira, D., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano‐Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 150
Yang, C., Chiu, M., Chen, T., Chang, H.-L., Liu, B.-H., & Yang, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170810 · Cited by 143
Fortea, J., Vilaplana, E., Alcolea, D. A., Carmona‐Iragui, M., Sánchez‐Saudinós, M., Sala, I., Antón‐Aguirre, S., González‐Ortiz, S., Medrano, S., Pegueroles, J., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24186 · Cited by 140
Self-citationBraak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 148
Self-citationSparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data
Initiative, A. D. N., Ye, J., Farnum, M. A., Yang, E., Verbeeck, R., Lobanov, V. S., Raghavan, N., Novak, G., DiBernardo, A., & Narayan, V. A. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-46 · Cited by 148
Self-citationMadsen, S. K., Ho, A. J., Hua, X., Saharan, P., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.002 · Cited by 146
Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 148
Self-citationIwatsubo, T., Iwata, A., Suzuki, K., Ihara, R., Arai, H., Ishii, K., Senda, M., Ito, K., Ikeuchi, T., Kuwano, R., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.009 · Cited by 142
Self-citationWolk (2012) · doi:10.1097/wco.0b013e328354ff0a · Cited by 147
Plasma apolipoprotein A1 as a biomarker for Parkinson disease
Qiang, J. K., Wong, Y. C., Siderowf, A. D., Hurtig, H. I., Xie, S. X., Lee, V. M. ‐., Trojanowski, J. Q., Yearout, D., Leverenz, J. B., Montine, T. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23872 · Cited by 142
Self-citationDickerson, B. C., Wolk, D. A., & Initiative, T. A. D. N. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199505 · Cited by 139
Alzheimer disease biomarkers are associated with body mass index
Vidoni, E. D., Townley, R. A., Honea, R. A., Burns, J. M., & Initiative, A. D. N. (2011) · Neurology · doi:10.1212/wnl.0b013e318238eec1 · Cited by 140
Self-citationCombined Plasma Biomarkers for Diagnosing Mild Cognition Impairment and Alzheimer’s Disease
Chiu, M., Yang, S., Horng, H. E., Yang, C., Chen, T., Chieh, J.-J., Chen, H.-H., Chen, T.-C., Ho, C.-S., Chang, S.-F., et al. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400129p · Cited by 136
Determining clinically meaningful decline in preclinical Alzheimer disease
Insel, P. S., Weiner, M., Mackin, R. S., Mormino, E., Lim, Y. Y., Stomrud, E., Palmqvist, S., Masters, C. L., Maruff, P. T., Hansson, O., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007831 · Cited by 128
Novel plasma biomarker surrogating cerebral amyloid deposition
KANEKO, N., Nakamura, A., Washimi, Y., Kato, T., Sakurai, T., Arahata, Y., Bundo, M., Takeda, A., Niida, S., Ito, K., et al. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.353 · Cited by 137
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
Apostolova, L. G., Hwang, K., Andrawis, J. P., Green, A. E., Babakchanian, S., Morra, J. H., Cummings, J. L., Toga, A. W., Trojanowski, J. Q., Shaw, L. M. J., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.003 · Cited by 144
Self-citationClassification of Alzheimer’s disease subjects from MRI using hippocampal visual features
Initiative, A. D. N., Ahmed, O. B., Benois‐Pineau, J., Michèle Allard, A., Amar, C. B., & Catheline, G. (2014) · Multimedia Tools and Applications · doi:10.1007/s11042-014-2123-y · Cited by 137
Self-citationA shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer's disease biomarkers
Kim, H., Lee, J. U., Song, S., Kim, S., & Sim, S. J. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.10.018 · Cited by 137
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136
Self-citationDementia risk and prevention by targeting modifiable vascular risk factors
Tariq, S., & Barber, P. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14132 · Cited by 140
APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls
Sampedro, F., Initiative, F. T. A. D. N., Vilaplana, E., de Leon, M. J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M., Sala, I., Sánchez-Saudinos, M.-B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5185 · Cited by 135
Self-citationEwers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S., Soininen, H., Maetzler, W., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.12.006 · Cited by 133
Self-citationDa, X., Toledo, J. B., Zee, J., Wolk, D. A., Xie, S. X., Ou, Y., Shacklett, A., Parmpi, P., Shaw, L. M. J., Trojanowski, J. Q., et al. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.11.010 · Cited by 144
Self-citationEvaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029868 · Cited by 135
Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging
Lui, J. K., Laws, S. M., Li, Q., Villemagne, V. L., Ames, D. J., Brown, B. M., Bush, A. I., Ruyck, K. D., Dromey, J. R., Ellis, K. A., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-090249 · Cited by 136
Amyloid-β–Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau
Desikan, R. S., McEvoy, L. K., Thompson, W. K., Holland, D., Brewer, J. B., Aisen, P. S. S., Sperling, R. A., Dale, A. M., & Initiative, A. D. N. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3354 · Cited by 139
Self-citationNation, D. A., Edmonds, E. C., Bangen, K. J., Delano‐Wood, L., Scanlon, B. K., Han, S. D., Edland, S. D., Salmon, D. P., Galasko, D. R., & Bondi, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4477 · Cited by 133
CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation
Kuhlmann, J., Andréasson, U., Pannee, J., Bjerke, M., Portelius, E., Leinenbach, A., Bittner, T., Korecka, M., Jenkins, R. G., Vanderstichele, H., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.05.014 · Cited by 139
Self-citationTranscranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia
Benussi, A., Lorenzo, F. D., Dell’Era, V., Cosseddu, M., Alberici, A., Caratozzolo, S., Cotelli, M. S., Micheli, A., Rozzini, L., Depari, A., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004232 · Cited by 137
Akyol, S., Ugur, Z., Yılmaz, A., Ustun, I., Gorti, S. K. K., Oh, K., McGuinness, B., Passmore, P., Kehoe, P. G., Maddens, M. E., et al. (2021) · Cells · doi:10.3390/cells10102591 · Cited by 138
Mattsson, N., Grinberg, L. T., Boxer, A. L., Ossenkoppele, R., Jonsson, M., Seeley, W., Ehrenberg, A. J., Spina, S., Janelidze, S., Rojas-Martinex, J., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200040 · Cited by 141
Structural Covariance of the Default Network in Healthy and Pathological Aging
Spreng, R. N., & Turner, G. R. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2261-13.2013 · Cited by 121
Metadata
- Authors
- Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M. ‐., Trojanowski, J. Q., & Initiative, A. D. N.
- Affiliations
- University of Pennsylvania (US)
- Fujirebio (Belgium) (BE)
- University of California San Diego (US)
- Mayo Clinic (US)
- University of Gothenburg (SE)
- Pfizer (United States) (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Eli Lilly (United States) (US)
- Corresponding author
- Shaw, Leslie M.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 65
- Issue
- 4
- Pages
- 403-413
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2696350
- OpenAlex
- W2008301592
- Cited by
- 2,065
- References
- 31
- Citations by year
- 2026: 59 · 2025: 82 · 2024: 110 · 2023: 89 · 2022: 114 · 2021: 125 · 2020: 136 · 2019: 141 · 2018: 129 · 2017: 135 · 2016: 121 · 2015: 146 · 2014: 131 · 2013: 130 · 2012: 136
- FWCI
- 85.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, AG 024904, P30AG010124, AG-10124, U19AG010483, U19AG024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, mild cognitive impairment, conversion to Alzheimer's disease, APOE ε4, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Diagnostic Imaging, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Retrospective Studies, ROC Curve, Sensitivity and Specificity, Threonine, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Statistics, Nonparametric, Area Under Curve, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
